Nanobiotix S.A. has reported promising results from its Phase 1 study evaluating JNJ-1900 (NBTXR3) as a treatment for patients with anti-PD-1-resistant melanoma. The findings, presented at the European Society for Medical Oncology (ESMO) Congress, indicate a 41.7% overall response rate and a median overall survival of 17.8 months, which could significantly impact treatment options for this challenging patient group.
Nanobiotix, a late-stage clinical biotechnology company, specializes in physics-based therapeutic approaches to enhance treatment outcomes for cancer patients. The company is listed on both the Nasdaq and Euronext Paris under the ticker symbols NBTX and NANO, respectively. It operates within the pharmaceutical preparations sector, focusing on innovative cancer therapies.
The recent filing reveals that on October 24, 2026, Nanobiotix issued a press release detailing the results of its Phase 1 Study 1100. The study involved 24 heavily pre-treated patients with advanced primary cutaneous melanoma, whose cancer had progressed after multiple therapies, including anti-PD-1 treatments. The results showed an acceptable safety profile and early efficacy signals, with 10 out of 24 patients achieving an overall response.
“Patients whose melanoma has progressed on anti-PD-1 therapy have limited options left. In this study, we saw responses in lesions that were injected and in lesions that were not,” said Dr. Jason Chan, who presented the findings.
This update is crucial for Nanobiotix as it continues to develop JNJ-1900 (NBTXR3) in combination with immune checkpoint inhibitors. The study's results may affect various stakeholders, including patients with advanced melanoma, healthcare providers, and investors looking for innovative cancer treatment options. The promising data could also influence the competitive landscape within the pharmaceutical preparations industry, prompting other companies to reassess their approaches to similar therapies.
Looking ahead, the filing does not specify what steps Nanobiotix will take next following these results. However, the encouraging findings suggest that further evaluation in randomized clinical trials may be warranted to solidify the efficacy of JNJ-1900 (NBTXR3) in treating patients resistant to anti-PD-1 therapies.